3115 Merryfield Row
Suite 300
San Diego, CA 92121
United States
858 465 6511
https://www.erasca.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 126
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman & CEO | 987.7k | N/A | 1972 |
Dr. David M. Chacko M.D. | CFO & Chief Business Officer | 666.09k | N/A | 1984 |
Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer | N/A | N/A | N/A |
Mr. Brian L. Baker CPA, M.S. | Senior Vice President of Finance | N/A | N/A | 1967 |
Ms. Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer | N/A | N/A | 1971 |
Dr. Robert Shoemaker Ph.D. | Senior Vice President of Research | N/A | N/A | 1981 |
Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1970 |
Ms. Minli Xie | Senior Vice President of Pharmaceutical Development & Operations | N/A | N/A | N/A |
Mr. Dawei Xuan Ph.D. | Senior Vice President of Clinical Pharmacology | N/A | N/A | N/A |
Mr. Les Brail Ph.D. | Senior Vice President of Early Clinical Development | N/A | N/A | N/A |
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 8.